Im amazed that BTA, like us plebs, has to rely on GSKs quarterly reports to see how Relenza is going... if I were to sell my product in exchange for a royalty, I'd also insist on good quality, & ongoing, performance monitoring... lessons for LANIflu...
us national antiviral stockpile inadequate, page-6
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)